BIO-TECHNE Corp
Company Stats
- Market Cap
- $11.4B
- as of Sep 30, 2026
- Shares Outstanding
- 156.8M
- Free Float
- 98.7%
Income Statement
- Revenue
- $1.2B
- Operating Income
- $251.9M
- Net Income
- $181.9M
- EBITDA
- $349.2M
- Revenue Growth, 3Y
- 2.2%
- FCF Margin, 3Y Avg
- 21.0%
- FCF Margin, Worst Year
- 20.4%
Cash Flow
- Free Cash Flow
- $263.2M
- FCF Yield
- 2.3%
- Owner FCF Yield
- 2.0%
Balance Sheet
- Cash & Equivalents
- $264.7M
Returns & Capital
- Dividends Paid
- $49.9M
- Dividend Yield
- 0.4%
- Dividend Payout, 3Y Avg
- 42.0%
- Share Repurchases
- $41.7M
- Buyback Yield, 3Y Avg
- 1.2%
- SBC, 3Y Avg
- $40.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2026 | $1.2B | $263.2M | 21.7% |
| FY2025 | $1.2B | $256.6M | 21.0% |
| FY2024 | $1.2B | $236.1M | 20.4% |
| FY2023 | $1.1B | $216.1M | 19.0% |
| FY2022 | $1.1B | $280.4M | 25.4% |
Annual filing data through FY ended June 30, 2026; shares and float as of October 22, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 24, 2026
Deals
Bio-Techne Shareholders Approve Merck KGaA's $11.3 Billion Cash Bid
June 25, 2026
Earnings Digest
BlackBerry Hits Cash Flow Milestone; M&A Hits Life Sciences, AI
June 25, 2026
Deals
Merck KGaA to Buy Bio-Techne in $11.3 Billion All-Cash Deal
Stronger demand supports expansion as pricing diverges
September 24, 2026
Deals
Bio-Techne Shareholders Approve Merck KGaA's $11.3 Billion Cash Bid
June 25, 2026
Earnings Digest
BlackBerry Hits Cash Flow Milestone; M&A Hits Life Sciences, AI
June 25, 2026
Deals
Merck KGaA to Buy Bio-Techne in $11.3 Billion All-Cash Deal